TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30661553

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Attention Control Training (ACT)
Number of subjects: 58
Study: 28203735

Group type: EXPERIMENTAL
Intervention: TXA
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 24218041

Group type: EXPERIMENTAL
Intervention: Vitreous samples from eyes with RRD
Number of subjects: 117

Group type: COMPARATOR
Intervention: Vitreous samples from eyes with macular hole or pucker
Number of subjects: 117
Study: 22653067

Group type: EXPERIMENTAL
Intervention: Eugenol concentrations at or below the International Fragrance Association standard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19902745

Group type: EXPERIMENTAL
Intervention: Single carbon fiber cage (group A)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Double carbon fiber cages (group B)
Number of subjects: 97
Study: 17252567

Group type: EXPERIMENTAL
Intervention: PDT (Photodynamic Therapy) with MAL (16% methyl aminolevulinate)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IPL (Intense Pulsed Light)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 15916891

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg bd
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (2 puffs bd)
Number of subjects: 160
Study: 11843370

Group type: EXPERIMENTAL
Intervention: Amnioinfusion (500 mL of normal saline over 30 minutes)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 200
Study: 9863486

Group type: EXPERIMENTAL
Intervention: Erythromycin 40 mg after placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Erythromycin 40 mg after atropine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Erythromycin 40 mg after sumatriptan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Erythromycin 200 mg after atropine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Erythromycin 200 mg after sumatriptan
Number of subjects: 30
Study: 8543964

Group type: EXPERIMENTAL
Intervention: EPV of 2
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: EPV of 5
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: EPV of 10
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: EPV of 15
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: EPV of 20
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: EPV of 25
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Original analysis with 36 events per variable
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Original analysis
Number of subjects: 673
Study: 2229750

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Surgical therapy in patients with proximal left anterior descending coronary artery stenosis ≥ 70% and ejection fraction < 0.50
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Surgical therapy in patients with three vessel coronary artery disease and ejection fraction < 0.50
Number of subjects: 2099
Study: 7410724

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage (expectancy condition)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-alcoholic beverage (control condition)
Number of subjects: 72
Study: 31538453

Group type: EXPERIMENTAL
Intervention: Chlo‐SITE (chlorhexidine based local drug delivery) applied in 1 pocket in 2 quadrants after full mouth disinfection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment in 2° and 3° quadrants)
Number of subjects: 60
Study: 27902641

Group type: EXPERIMENTAL
Intervention: Neostigmine (50 μg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neostigmine followed by Sugammadex (50 μg/kg neostigmine, then 2 mg/kg sugammadex after 3 min)
Number of subjects: 18
Study: 25710559

Group type: EXPERIMENTAL
Intervention: HICE (20 min cycling @ just above ventilatory threshold)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HIIE (10 X 1‐min @ ∼90% peak aerobic power)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HICE
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HIIE
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study: 23373541

Group type: EXPERIMENTAL
Intervention: Covered SEMS
Number of subjects: 68

Group type: COMPARATOR
Intervention: Uncovered SEMS
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both types of SEMS
Number of subjects: 68
Study: 21275083

Group type: EXPERIMENTAL
Intervention: Metacognitive training for schizophrenia patients (MCT+)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cognitive remediation (active control)
Number of subjects: 48
Study: 19615696

Group type: EXPERIMENTAL
Intervention: Interferon beta (IFNbeta) treatment
Number of subjects: 2570
Study: 17302058

Group type: EXPERIMENTAL
Intervention: Wendan Tablet (WT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 16830065

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 47
Study: 12765886

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg kg(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 11104345

Group type: EXPERIMENTAL
Intervention: Supratentorial radiation dose of 25 Gy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Supratentorial radiation dose of 35 Gy
Number of subjects: 36
Study: 8675231

Group type: EXPERIMENTAL
Intervention: alfa 2a interferon
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 1651860

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg on day 1, plus 250 mg/day on days 2-5)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (625 mg every eight hours for ten days)
Number of subjects: 110
Study: 7042074

Group type: EXPERIMENTAL
Intervention: Peptichemio (75-100 mg/m2 IV q 3-4 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: L-PAM (30-40 mg/m2 IV q 3-4 weeks)
Number of subjects: 56
Study: 31658494

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous salbutamol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous tobramycin
Number of subjects: 12
Study: 31360729

Group type: EXPERIMENTAL
Intervention: Tramadol plus ramosetron (group R, n=49)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tramadol only (group N, n=51)
Number of subjects: 110
Study: 28882926

Group type: EXPERIMENTAL
Intervention: ProAsk intervention delivered on a tablet device
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ProAsk intervention
Number of subjects: 88
Study: 24975366

Group type: EXPERIMENTAL
Intervention: Risperidone (single-dose, two-period crossover study)
Number of subjects: 70
Study: 23388524

Group type: EXPERIMENTAL
Intervention: Therapist-led groups (TLG)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Self-help groups (SHG)
Number of subjects: 99
Study: 21501328

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once a day for 12 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg once a day for 12 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 48
Study: 19709754

Group type: EXPERIMENTAL
Intervention: Escitalopram, 10 mg
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Combination of escitalopram and bupropion
Number of subjects: 375
Study: 17393613

Group type: EXPERIMENTAL
Intervention: Point-stimulation plus chlorimipramine (PS+Chl)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorimipramine (Chl)
Number of subjects: 60
Study: 15117326

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b plus ribavirin (RBV) 1000-1200 mg/day for 48 weeks (Study 1)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b plus ribavirin (RBV) 1000-1200 mg/day for 4 weeks followed by three times weekly dosing for 44 weeks (Study 2)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: RBV dose reduction
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b daily use
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Sex (Women vs Men)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Baseline factors (creatinine clearance, Hb levels, age)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Baseline weight
Number of subjects: 677
Study: 11208843

Group type: EXPERIMENTAL
Intervention: 4-week chemotherapy regimen (vincristine and actinomycin D)
Number of subjects: 382

Group type: COMPARATOR
Intervention: 8-week chemotherapy regimen (vincristine and actinomycin D)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: No further treatment (NFT) for stage I favorable histology (n = 5)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: VCR and AMD for 17 weeks (AV) for stage I standard histology or anaplasia (n = 244)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: VCR, AMD, and anthracycline for 27 weeks (AVE) for stages II and III (n = 75)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: VCR, AMD, anthracycline, and ifosfamide for 36 weeks (DEVI) for anaplastic tumors staged higher than I (n = 14)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: AVE with 15-Gy abdominal irradiation (RTH) for stages IIN1 and III (n = 56)
Number of subjects: 382
Study: 9777135

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 0
Study: 7883388

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg t.i.d. intravenously for 3-21 days (mean 5.4 days)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg/500 mg t.i.d. intravenously for 3-17 days (mean 5.1 days)
Number of subjects: 109
Study: 3284283

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine chewing gum (n = 62)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine chewing gum (n = 54)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Group counselling with nicotine gum (2 mg or 4 mg)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Advice only control group (n = 56)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Self-reported chronic bronchitis subgroup
Number of subjects: 172
Study: 31999399

Group type: EXPERIMENTAL
Intervention: Nutrition education combined with the provision of complementary foods
Number of subjects: 243

Group type: COMPARATOR
Intervention: Baseline data
Number of subjects: 243

Group type: COMPARATOR
Intervention: Endline data
Number of subjects: 243
Study: 30076593

Group type: EXPERIMENTAL
Intervention: Culturally adapted GenerationPMTO® intervention for Latino/a immigrant families
Number of subjects: 39
Study: 28272164

Group type: EXPERIMENTAL
Intervention: FTC/TAF
Number of subjects: 663

Group type: COMPARATOR
Intervention: FTC/TDF
Number of subjects: 663
Study: 25528415

Group type: EXPERIMENTAL
Intervention: Levonorgestrel emergency contraception
Number of subjects: 1731
Study: 23085475

Group type: EXPERIMENTAL
Intervention: Instruction (select a healthy meal)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Instruction + Information (select a healthy meal with nutrition information)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (served normally)
Number of subjects: 124
Study: 21115872

Group type: EXPERIMENTAL
Intervention: Topotecan Weekly (Tw) 4 mg/m²/week administered on days 1, 8, and 15
Number of subjects: 194

Group type: COMPARATOR
Intervention: Conventional 5-Day Schedule (Tc) 1.25 mg/m²/day on days 1 to 5
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Topotecan Weekly (Tw)
Number of subjects: 194
Study: 19286582

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin daily
Number of subjects: 94

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 94
Study: 16854404

Group type: EXPERIMENTAL
Intervention: Recutin (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Polybutin (100 mg)
Number of subjects: 24
Study: 15264961

Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling curriculum
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (initial control before intervention crossover)
Number of subjects: 26
Study: 12136489

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ID)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Molsidomin
Number of subjects: 105
Study: 10451042

Group type: EXPERIMENTAL
Intervention: Acute low-back pain patients
Number of subjects: 180

Group type: COMPARATOR
Intervention: Age- and sex-matched controls
Number of subjects: 180
Study: 8665993

Group type: EXPERIMENTAL
Intervention: BAY t 7207 (20 mg)
Number of subjects: 8
Study: 2225152

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5% eye drops administered three times a day from the day prior to operation to the 10th day after operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered three times a day from the day prior to operation to the 10th day after operation
Number of subjects: 0
Study: 342962

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 28267947

Group type: EXPERIMENTAL
Intervention: Ambu® AuraGain™
Number of subjects: 100

Group type: COMPARATOR
Intervention: LMA Supreme™ Second Seal™
Number of subjects: 100
Study: 25546164

Group type: EXPERIMENTAL
Intervention: Voglibose/metformin fixed-dose combination (FDC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Coadministered individual voglibose and metformin tablets
Number of subjects: 28
Study: 23690755

Group type: EXPERIMENTAL
Intervention: Facilitation of local stakeholder groups (laywomen facilitated monthly meetings for 3 years)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Facilitation of local stakeholder groups
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no facilitation of local stakeholder groups)
Number of subjects: 90
Study: 22215335

Group type: EXPERIMENTAL
Intervention: Exercise training program (16 weeks, including warm-up, aerobic exercises on standing cycles, resistance exercises with Thera-Band)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 15
Study: 19139323

Group type: EXPERIMENTAL
Intervention: Tailored letter and enhanced management
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Nontailored letter and enhanced management
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Tailored letter and nonenhanced management
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Nontailored letter and nonenhanced management
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Enhanced office and patient management
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Tailored letter
Number of subjects: 599
Study: 17338610

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mg/kg intravenously as a bolus followed by a continuous infusion of 10 mg/kg/hr starting 15 minutes before induction of sedation.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no magnesium sulfate).
Number of subjects: 50
Study: 15333537

Group type: EXPERIMENTAL
Intervention: Staples
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 20
Study: 11370752

Group type: EXPERIMENTAL
Intervention: Cessation of weekly fluoride rinsing (test group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Weekly rinsing with 0.2% sodium fluoride solution (control group)
Number of subjects: 60
Study: 9112137

Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg‐1 ketorolac
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.9 mg x kg‐1 ketorolac
Number of subjects: 14
Study: 1439621

Group type: EXPERIMENTAL
Intervention: Arthrotec (50 mg diclofenac + 200 micrograms misoprostol)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Diclofenac (50 mg)
Number of subjects: 619
Study: 4091997

Group type: EXPERIMENTAL
Intervention: Ethanol consumption (80 g per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (abstinence from ethanol)
Number of subjects: 10
Study: 30795711

Group type: EXPERIMENTAL
Intervention: Multimedia educational intervention (4-week program followed by telephone consultations at Weeks 12 and 24)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no multimedia educational intervention)
Number of subjects: 123
Study: 30813546

Group type: EXPERIMENTAL
Intervention: Vegan meal (V-meal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard meat meal (M-meal)
Number of subjects: 20
Study: 27770293

Group type: EXPERIMENTAL
Intervention: Brief Internet intervention (CheckYourDrinking.net)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Extended Internet intervention (AlcoholHelpCentre.net)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Combined analyses of both interventions
Number of subjects: 490
Study: 25779902

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (HN001)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis HN019 (HN019)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 23344135

Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions for HR youth
Number of subjects: 2643

Group type: COMPARATOR
Intervention: Treatment as usual (statutory drug education) for LR youth
Number of subjects: 2643
Study: 21155908

Group type: EXPERIMENTAL
Intervention: Cross-intolerance (CI) to NSAIDs, primarily involving propionic acid derivatives like ibuprofen.
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Selective responders (SR) to NSAIDs, primarily involving pyrazolones.
Number of subjects: 659
Study: 19215336

Group type: EXPERIMENTAL
Intervention: 0.1 mg entecavir
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 0.5 mg entecavir
Number of subjects: 66
Study: 17270090

Group type: EXPERIMENTAL
Intervention: Cooked meat meal
Number of subjects: 32

Group type: COMPARATOR
Intervention: Meat-free meal
Number of subjects: 32
Study: 14709952

Group type: EXPERIMENTAL
Intervention: Vitamin E (1200 IU/d for 12 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11550573

Group type: EXPERIMENTAL
Intervention: Standard inactivated whole‐virion influenza vaccine (0.5 ml subcutaneously in a single injection)
Number of subjects: 4518

Group type: EXPERIMENTAL
Intervention: Standard inactivated whole‐virion influenza vaccine (intranasally in two administrations)
Number of subjects: 4518

Group type: COMPARATOR
Intervention: Standard inactivated whole‐virion influenza vaccine (intranasally)
Number of subjects: 4518

Group type: EXPERIMENTAL
Intervention: Preparation 'Amber elixir plus'
Number of subjects: 4518
Study: 9509882

Group type: EXPERIMENTAL
Intervention: Salford static knee instrument (SSKI)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Al‐Turaiki device
Number of subjects: 14
Study: 8112372

Group type: EXPERIMENTAL
Intervention: Intravenous 14C‐fosinoprilat (7.5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral 14C‐fosinopril sodium (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral fosinopril sodium (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fosinoprilat concentration vs. serum ACE activity
Number of subjects: 6

Group type: COMPARATOR
Intervention: Haemodialysis (4 hours)
Number of subjects: 6
Study: 3086388

Group type: EXPERIMENTAL
Intervention: Rifampin therapy (5 days) in combination with penicillin or erythromycin (10-14 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Penicillin or erythromycin (10-14 days)
Number of subjects: 9
Study: 2682692

Group type: EXPERIMENTAL
Intervention: Lithium addition to TCA
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31926037

Group type: EXPERIMENTAL
Intervention: Blood donors with lead concentrations over the limit for transfusions in premature infants (0.09 μmol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood donors with mercury concentrations over the suggested limit (23.7 nmol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood donors with cadmium concentrations over the limit (16 nmol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood donors with perfluorooctanoate (PFOA) concentrations over the suggested limit (0.91 ng/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood donors with perfluorooctane sulfonate (PFOS) concentrations over the suggested limit (0.91 ng/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PFAS and heavy metal concentrations in relation to donor's age
Number of subjects: 0
Study: 31424677

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 102
Study: 27884065

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (ONA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Daewoong BTA (NBT)
Number of subjects: 35
Study: 26406397

Group type: EXPERIMENTAL
Intervention: 10-week Nordic walking training program
Number of subjects: 32
Study: 23609425

Group type: EXPERIMENTAL
Intervention: Induced sputum (IS) analysis in patients with active sarcoidosis
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Sputum induction by inhalation of hypertonic saline
Number of subjects: 86
Study: 22078240

Group type: EXPERIMENTAL
Intervention: Tailored nutrition intervention (five-a-day program)
Number of subjects: 400
Study: 19451828

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 292

Group type: COMPARATOR
Intervention: Standard-of-care antipsychotics
Number of subjects: 292
Study: 16433729

Group type: EXPERIMENTAL
Intervention: Transdermal alcohol monitoring device (anklet)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Self-reported drinking log and transdermal alcohol monitoring device
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Transdermal alcohol monitoring device
Number of subjects: 44